In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Punit Kumar, the Executive Director of Customer Engagement for the US Enterprise Portfolio at Novartis, to dive into why execution excellence matters more than hype, how AI agents are freeing up your team from manual work to focus on high-impact insights, and the counterintuitive skill that matters most in pharma today: getting comfortable being uncomfortable.What You’ll Learn:How to shift from talking about AI to executing on itThe real value of fit for purpose commercial operationsWhy upskilling in functional expertise is non-negotiable for leadersHow to reframe AI adoption from threat to opportunity with your teamThe quantifiable impact of AI-enabled field effectivenessHow to get comfortable being uncomfortable as a competitive advantagePunit Kumar is the Executive Director of Customer Engagement for the US Enterprise Portfolio at Novartis, bringing over two decades of experience across leading pharmaceutical companies, including Regeneron and Otsuka. A recognized expert in building fit for purpose commercial operations infrastructure and driving organizational transformation at scale, Punit has successfully launched multiple blockbuster therapies while pioneering the integration of AI agents to enhance efficiency and decision-making across targeting, call planning, incentive compensation, and analytics functions.Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice.The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations.Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.Episode Resources:Punit Kumar on LinkedInNovartis WebsiteJonathan Kaskey on LinkedInXSUNT Corporation WebsiteOr join the Pharma Sessions Substack:www.pharmasessions.substack.comPharma Sessions is handcrafted by our friends over at: fame.so